Pharmaceutical - Diabetes


Current filters:


Popular Filters

201 to 225 of 402 results

Zydus' diabetes drug Lipaglyn becomes India's first NCE to reach the market


Indian drugmaker Zydus Cadila today (June 5) made a breakthrough in its research efforts with Lipaglyn…

Asia-PacificDiabetesLipaglynPharmaceuticalRegulationZydus Cadila

GW Pharma posts six-month results; progresses cannabinoid pipeline including into diabetes and UC


UK biopharma company GW Pharmaceuticals (AIM: GWP), which is developing and commercializing novel therapeutics…

DiabetesFinancialGastro-intestinalsGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Novo Nordisk files Tresiba/Victoza combo IDegLira for EU approval


Danish insulin giant Novo Nordisk (NOV: N) said today (May 31) that it has submitted a marketing authorization…

DiabetesEuropeIDegLiraNovo NordiskPharmaceuticalRegulationTresibaVictoza

UK's NICE backs NHS use of Bristol-Myers/AstraZeneca's Forxiga


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today (May 30) issued…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial


Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

FDA allows marketing of first A1c test labeled for diagnosing diabetes, from Roche


The US Food and Drug Administration yesterday (May 23) announced that it is allowing marketing of the…

Cobas Integra 800DiabetesPharmaceuticalRegulationRoche

Positive new data on Novartis' Galvus in elderly type 2 diabetes patients


Results of the INTERVAL study were published on line in The Lancet today (May 23) and for the first time…


Is the diabetes market facing a blockbuster-free future?


Japanese drug major Takeda's (TYO: 4502) recently announced positive late-stage results for new type…

DiabetesfasiglifamMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceuticals

Diabetes drugs market forecast to reach $55.3 billion in 2017, with further growth to 2023


A new report by Visiongain predicts the world market for diabetes medications will reach $55.3bn in 2017.…

DiabetesGlobalMarkets & MarketingPharmaceuticalResearch

Sanofi plans acceleration of expansion into Ukraine this year


French drug major Sanofi (Euronext: SAN) is considering expanding its presence in Ukraine this year,…

Cardio-vascularDiabetesEuropeMarkets & MarketingPharmaceuticalProductionSanofi

Abide Therapeutics in up to $430 million deal with Merck & Co for type 2 diabetes and metabolic disease


Privately-held biopharma firm Abide Therapeutics has entered into a collaboration agreement with US…

Abide TherapeuticsDiabetesLicensingMerck & CoMetabolicsPharmaceuticalResearch

US Judge throws out verdict in Takeda Actos case


The US subsidiary of Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) USA announced that,…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Emisphere earns $10 million on amended deal with Novo Nordisk


USA-based Emisphere Technologies (OTCBB: EMIS) says that it has agreed with Danish insulin giant Novo…

DiabetesEmisphereLicensingNovo NordiskPharmaceuticalResearch

Takeda considering options over US Actos court ruling


The US subsidiary of Japan's largest drugmaker, Takeda Pharmaceuticals (TYO 4502), says that in the case…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Merck & Co opens new $120 million manufacturing plant in China


US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Brazil to resume human insulin production, with a $200+ investment


The resumption of national human insulin production was announced in Brazil this week, at an event in…

Biomm TechnologyDiabetesFiocruzInsulinPharmaceuticalProductionSouth America

Lilly's diabetes drug dulaglutide does well in two additional trials


US drug major Eli Lilly (NYSE: LLY) has released positive top-line results of two additional Phase III…

DiabetesdulaglutideEli LillyPharmaceuticalResearch

Eli Lilly views additional $180 million investment to expand insulin making in Indianapolis


US pharma major Eli Lilly (NYSE: LLY) says that it is working closely with the City on a proposal to…

DiabetesFinancialInsulinLillyNorth AmericaPharmaceuticalProduction

201 to 225 of 402 results

Back to top